Across TCGA pan-cancer cohorts, TRAV7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAV7 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRAV7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV7 expression acts as an unfavorable survival marker.

STAD, LUSC, and BLCA are the cancer types where TRAV7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
LUSC	OS	Median	All	0.152	0.762	.001	12	view →
BLCA	OS	Median	All	0.166	0.616	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRAV7 tumor-vs-normal RNA expression · all TRAV7 data types